|JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial|
|Cao, Hongbo1; Ren, Ming1; Guo, Liping2; Shang, Hongcai1,3; Zhang, Junhua3; Song, Yuzhen1; Wang, Hui1; Wang, Baohe1; Li, Xiantao1; Hu, Jing3; Wang, Xuemei4; Wang, Dehui5; Chen, Jianzong6; Li, Shuanglei7; Chen, Liming8|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, Research & Experimental|
|研究领域[WOS]||Research & Experimental Medicine|
|关键词[WOS]||IMPAIRED GLUCOSE-TOLERANCE ; DIABETES-MELLITUS|
Background: Pre-diabetes is a growing health concern where a large percentage of these patients develop full type 2 diabetes. Effective interventions on pre-diabetes can prevent or delay the occurrence or development of diabetes. Pharmaco-dynamics and pre-clinical of JinQi-Jiangtang tablets (JQJT) suggest that it could be benefit for pre-diabetes.
Methods/Design: Randomized controlled trial (RCT) is implemented in this study. The study term is 24 months (12 months for intervention and 12 months for follow up). Participants are recruited from four cities of China: Beijing, Tianjin, Xi′an and Nanning. Four hundred participants are randomized to treatment group (JQJT tablets) and control group (Placebo); two hundred participants each. People being included in this study must have been diagnosed as pre-diabetes via western medicine criteria and traditional Chinese medicine (TCM) criteria. The endpoint indexes include: incidence of diabetes mellitus and reversion rate. Primary outcome indexes include: oral glucose tolerance test; insulin releasing test; glycosylated hemoglobin (HA1c). Secondary outcome indexes include: score of the Short Form 36 Health Survey Questionnaire (SF-36); score of TCM symptoms; blood lipid test. Indexes of safety include: general medical examination; blood and urine regular test; electrocardiogram (ECG), liver function (ALT) and renal function (BUN, Creatinine) test; record of adverse event, such as headache, faint, etc. Qualitative control will be implemented and a number of standard operating processes (SOPs) will be formed throughout the study: laboratory quality control measures; compliance control for researchers and participants; researcher training before study; supervision; investigational drug management and others.
Discussion: The aim of this study is to evaluate the effectiveness and safety of JinQi JiangTang (JQJT) tablets for the treatment of patients with pre-diabetes.
|资助机构||National Basic Research Program of China (973 program)|
|作者单位||1.Evidence Based Med Ctr Tianjin, Tianjin 300193, Peoples R China|
2.Xijing Hosp, Dept TCM, Xian 710032, Peoples R China
3.Tianjin Univ TCM, Clin Assessment Inst, Tianjin 300193, Peoples R China
4.Tianjin Univ TCM, Baokang Hosp, Tianjin 300193, Peoples R China
5.Peking Univ, Hosp 1, Dept Integrated Chinese & Western Med, Beijing 100034, Peoples R China
6.Tianjin Univ TCM, Affiliated Hosp 2, Dept Endocrinol, Tianjin 300150, Peoples R China
7.Guangxi Coll TCM, Affiliated Hosp 1, Dept Endocrinol, Nanning 530023, Peoples R China
8.Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin 300211, Peoples R China
|Cao, Hongbo,Ren, Ming,Guo, Liping,et al. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial[J]. TRIALS,2010,11.|
|APA||Cao, Hongbo.,Ren, Ming.,Guo, Liping.,Shang, Hongcai.,Zhang, Junhua.,...&Chen, Liming.(2010).JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial.TRIALS,11.|
|MLA||Cao, Hongbo,et al."JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial".TRIALS 11(2010).|